Publication Personal Formatting |
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. Jessen M, Gertzmann D, Liss F, Zenk F, Bähner L, Schöffler V, Schulte C, Maric HM, Ade CP, von Eyss B, Gaubatz S. Oncogene. 2024 Feb;43(8):578-593. doi: 10.1038/s41388-023-02926-w. Epub 2024 Jan 5.
|
Oncogenic YAP mediates changes in chromatin accessibility and activity that drive cell cycle gene expression and cell migration. Fetiva MC, Liss F, Gertzmann D, Thomas J, Gantert B, Vogl M, Sira N, Weinstock G, Kneitz S, Ade CP, Gaubatz S. Nucleic Acids Res. 2023 May 22;51(9):4266-4283. doi: 10.1093/nar/gkad107.
|
Expression of the cytokinesis regulator PRC1 results in p53-pathway activation in A549 cells but does not directly regulate gene expression in the nucleus. Hanselmann S, Gertzmann D, Shin WJ, Ade CP, Gaubatz S. Cell Cycle. 2023 Feb;22(4):419-432. doi: 10.1080/15384101.2022.2122258. Epub 2022 Sep 22.
|
|
| Last update Publications 13.01.2024 |
|